Home › Funds › First Turn Management, LLC › XENE

First Turn Management, LLC position in XENE

XENON PHARMACEUTICALS INC · Health Care

First Turn Management, LLC reported holding 297,060 shares of XENE (XENON PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$11.0M, representing 1.47% of its reported portfolio and ranking #33 among its reported holdings. First Turn Management, LLC has disclosed XENE holdings in 12 of the last 12 reported quarters, going back to Q4 2023.

Latest position (Q3 2026)297.06K sh
Reported value held$11.05M
Portfolio Weight1.47%
First reportedQ4 2023
Last changeReduce
Updated2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

How First Turn Management, LLC's XENE position evolved

First Turn Management, LLC first disclosed a stake in XENE in Q4 2023 at 680,389 shares (US$31.3M). The position peaked in Q1 2026 at 786,844 shares, worth US$45.8M. Across 12 filings, First Turn Management, LLC increased the stake 2 time(s), trimmed it 6 time(s) and left it unchanged 3 time(s). The most recent filing (Q3 2026) shows 297,060 shares valued at US$11.0M — a reduction of -303,140 shares quarter over quarter.. Notable position changes include a 50% trim in Q2 2024 (shares were roughly flat over the following quarter), a 111% increase in Q4 2024 (shares fell 14% over the following quarter), a 51% trim in Q3 2026 (shares rose 9% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2023 680.39K $31.34M New
Q1 2024 680.39K $29.29M Hold
Q2 2024 339.88K $13.25M Reduce
Q3 2024 325.22K $12.80M Reduce
Q4 2024 684.99K $26.85M Add
Q1 2025 683.45K $22.93M Hold
Q2 2025 660.62K $20.68M Reduce
Q3 2025 799.74K $32.11M Add
Q4 2025 799.74K $35.84M Hold
Q1 2026 786.84K $45.75M Reduce
Q2 2026 600.20K $36.23M Reduce
Q3 2026 297.06K $11.05M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About XENE and 13F data

XENE (XENON PHARMACEUTICALS INC) is a Health Care company. 32 other funds we track also report a position in XENE — the largest reported positions include Avoro Capital Advisors LLC (US$204.5M), DRIEHAUS CAPITAL MANAGEMENT LLC (US$132.3M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$97.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding XENE

All XENE fund holders →

FAQ

How long has First Turn Management, LLC held XENE?

First Turn Management, LLC has disclosed XENE holdings in 12 of the last 12 reported quarters, going back to Q4 2023.

What is First Turn Management, LLC's current position in XENE?

As of Q3 2026, First Turn Management, LLC holds 297.06K shares of XENE (XENON PHARMACEUTICALS INC), valued at $11.05M, representing 1.47% of its reported portfolio and ranking #33.

Has First Turn Management, LLC been buying or selling XENE?

In the latest 13F filing (Q3 2026), First Turn Management, LLC reduced its position in XENE. The position peaked in Q1 2026 at 786.84K shares.

Which other funds hold XENE?

Other major institutional holders of XENE include Avoro Capital Advisors LLC, DRIEHAUS CAPITAL MANAGEMENT LLC, DEERFIELD MANAGEMENT COMPANY, L.P., among 32 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.